Asano Shogo, Suzuki Atsushi, Itoh Mitsuyasu
Division of Endocrinology and Metabolism, Department of Internal Medicine, Fujita Health University.
Clin Calcium. 2009 Aug;19(8):1179-85.
Bisphosphonates (BPs) are now widely used for the prevention of osteoporotic fracture. The elevation of bone turnover markers (BTM) is an independent risk factor for the bone fracture, and their significant decrease with BPs treatment is considered to reflect BPs' efficacy to "adjust" bone turnover. A large-scale study so far showed that BPs continuously suppress both BTM levels and the incidence of fracture as long as 7 to 10 years, though possible deterioration of bone strength with long-term severe suppression of BTM has been pointed out.
双膦酸盐(BPs)目前广泛用于预防骨质疏松性骨折。骨转换标志物(BTM)升高是骨折的独立危险因素,双膦酸盐治疗后其显著降低被认为反映了双膦酸盐“调节”骨转换的疗效。迄今为止,一项大规模研究表明,双膦酸盐可连续7至10年抑制BTM水平和骨折发生率,不过也有人指出,长期严重抑制BTM可能会导致骨强度下降。